- Home
- SAFE vs HELP Comparison
SAFE vs HELP Comparison
Compare SAFE & HELP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SAFE | HELP |
|---|---|---|
| Founded | 2016 | 2019 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 842.7M | 862.2M |
| IPO Year | 1999 | 2020 |
Fundamental Metrics
Financial Performance| Metric | SAFE | HELP |
|---|---|---|
| Price | $11.97 | $10.50 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 11 | 11 |
| Target Price | $17.60 | ★ $39.99 |
| AVG Volume (30 Days) | 621.7K | ★ 1.6M |
| Earning Date | 11-04-2026 | 11-12-2026 |
| Dividend Yield | ★ 5.87% | N/A |
| EPS Growth | ★ 7.43 | N/A |
| EPS | ★ 0.82 | N/A |
| Revenue | ★ $385,552,000.00 | N/A |
| Revenue This Year | $12.09 | N/A |
| Revenue Next Year | $4.69 | N/A |
| P/E Ratio | $14.71 | ★ N/A |
| Revenue Growth | ★ 5.43 | N/A |
| 52 Week Low | $11.60 | $3.76 |
| 52 Week High | $17.45 | $15.15 |
Technical Indicators
Market Signals| Indicator | SAFE | HELP |
|---|---|---|
| Relative Strength Index (RSI) | 29.47 | 39.98 |
| Support Level | $11.60 | $4.41 |
| Resistance Level | $16.43 | $14.75 |
| Average True Range (ATR) | 0.30 | 0.79 |
| MACD | 0.08 | -0.24 |
| Stochastic Oscillator | 33.07 | 16.69 |
Price Performance
Historical ComparisonAbout SAFE Safehold Inc. New
Safehold Inc is a REIT that operates its business by acquiring, managing, and capitalizing ground leases. Ground leases are long-term contracts between the landlord (the Company) and a tenant or leaseholder. Ground leases generally represent ownership of the land underlying commercial real estate projects that are net leased by the fee owner of the land to the owners/operators of the real estate projects built thereon.
About HELP Cybin Inc. Common Stock
Helus Pharma Inc, the commercial operating name of Cybin Inc, is a clinical-stage pharmaceutical company focused on developing proprietary neuroactive compounds, referred to as NSAs, which are synthetic molecules designed to target serotonin pathways. The company's programs are aimed at treating mental health conditions such as depression and anxiety. Its pipeline includes HLP003, which is in clinical development for the adjunctive treatment of depressive disorder, and HLP004, which is in clinical development for generalized anxiety disorder. The company also conducts research on additional investigational compounds.